nodes	percent_of_prediction	percent_of_DWPC	metapath
Fluticasone Propionate—CYP3A4—Imiquimod—skin cancer	0.1	0.192	CbGbCtD
Fluticasone Propionate—CYP3A4—Temozolomide—skin cancer	0.1	0.192	CbGbCtD
Fluticasone Propionate—CYP3A4—Vismodegib—skin cancer	0.0695	0.133	CbGbCtD
Fluticasone Propionate—CYP3A7—Docetaxel—skin cancer	0.0644	0.124	CbGbCtD
Fluticasone Propionate—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.0644	0.124	CbGbCtD
Fluticasone Propionate—CYP3A4—Vemurafenib—skin cancer	0.0549	0.105	CbGbCtD
Fluticasone Propionate—CYP3A5—Docetaxel—skin cancer	0.0483	0.0928	CbGbCtD
Fluticasone Propionate—CYP3A4—Docetaxel—skin cancer	0.0189	0.0362	CbGbCtD
Fluticasone Propionate—Fluocinonide—SMO—skin cancer	0.00639	0.837	CrCbGaD
Fluticasone Propionate—NR3C2—Preimplantation Embryo—PADI6—skin cancer	0.00335	0.232	CbGpPWpGaD
Fluticasone Propionate—PGR—blood vessel—skin cancer	0.00273	0.0711	CbGeAlD
Fluticasone Propionate—PLA2G4A—nipple—skin cancer	0.00261	0.068	CbGeAlD
Fluticasone Propionate—NR3C2—nipple—skin cancer	0.00213	0.0553	CbGeAlD
Fluticasone Propionate—NR3C1—nerve—skin cancer	0.00201	0.0523	CbGeAlD
Fluticasone Propionate—PGR—nipple—skin cancer	0.00198	0.0514	CbGeAlD
Fluticasone Propionate—PLA2G4A—connective tissue—skin cancer	0.00185	0.0483	CbGeAlD
Fluticasone Propionate—PLA2G4A—mammalian vulva—skin cancer	0.00153	0.0397	CbGeAlD
Fluticasone Propionate—NR3C2—connective tissue—skin cancer	0.00151	0.0392	CbGeAlD
Fluticasone Propionate—PGR—connective tissue—skin cancer	0.0014	0.0365	CbGeAlD
Fluticasone Propionate—PGR—epithelium—skin cancer	0.00133	0.0346	CbGeAlD
Fluticasone Propionate—PLA2G4A—female reproductive system—skin cancer	0.00131	0.034	CbGeAlD
Fluticasone Propionate—SERPINA6—female reproductive system—skin cancer	0.0013	0.0339	CbGeAlD
Fluticasone Propionate—NR3C2—mammalian vulva—skin cancer	0.00124	0.0323	CbGeAlD
Fluticasone Propionate—NR3C1—nipple—skin cancer	0.00114	0.0297	CbGeAlD
Fluticasone Propionate—NR3C1—neck—skin cancer	0.00113	0.0294	CbGeAlD
Fluticasone Propionate—NR3C2—Preimplantation Embryo—NKX2-1—skin cancer	0.0011	0.0764	CbGpPWpGaD
Fluticasone Propionate—SERPINA6—head—skin cancer	0.00109	0.0283	CbGeAlD
Fluticasone Propionate—NR3C2—female reproductive system—skin cancer	0.00106	0.0277	CbGeAlD
Fluticasone Propionate—PGR—lymphoid tissue—skin cancer	0.00103	0.0267	CbGeAlD
Fluticasone Propionate—PGR—female reproductive system—skin cancer	0.000989	0.0257	CbGeAlD
Fluticasone Propionate—Mental disorder—Imiquimod—skin cancer	0.00093	0.00222	CcSEcCtD
Fluticasone Propionate—Bronchospasm—Bleomycin—skin cancer	0.000926	0.00221	CcSEcCtD
Fluticasone Propionate—Oropharyngeal pain—Docetaxel—skin cancer	0.000926	0.00221	CcSEcCtD
Fluticasone Propionate—Erythema—Imiquimod—skin cancer	0.000924	0.00221	CcSEcCtD
Fluticasone Propionate—Malnutrition—Imiquimod—skin cancer	0.000924	0.00221	CcSEcCtD
Fluticasone Propionate—Arthralgia—Vemurafenib—skin cancer	0.000922	0.0022	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000916	0.00219	CcSEcCtD
Fluticasone Propionate—Lacrimation increased—Docetaxel—skin cancer	0.000914	0.00218	CcSEcCtD
Fluticasone Propionate—Vomiting—Vismodegib—skin cancer	0.00091	0.00217	CcSEcCtD
Fluticasone Propionate—Rash—Vismodegib—skin cancer	0.000902	0.00216	CcSEcCtD
Fluticasone Propionate—Dermatitis—Vismodegib—skin cancer	0.000901	0.00215	CcSEcCtD
Fluticasone Propionate—NR3C2—head—skin cancer	0.000889	0.0231	CbGeAlD
Fluticasone Propionate—Face oedema—Temozolomide—skin cancer	0.000887	0.00212	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Fluorouracil—skin cancer	0.000886	0.00212	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Vemurafenib—skin cancer	0.000884	0.00211	CcSEcCtD
Fluticasone Propionate—Infection—Vemurafenib—skin cancer	0.000878	0.0021	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Vemurafenib—skin cancer	0.000867	0.00207	CcSEcCtD
Fluticasone Propionate—Skin disorder—Vemurafenib—skin cancer	0.000859	0.00205	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Imiquimod—skin cancer	0.000857	0.00205	CcSEcCtD
Fluticasone Propionate—Nausea—Vismodegib—skin cancer	0.00085	0.00203	CcSEcCtD
Fluticasone Propionate—Agitation—Imiquimod—skin cancer	0.000849	0.00203	CcSEcCtD
Fluticasone Propionate—Pneumonia—Bleomycin—skin cancer	0.000845	0.00202	CcSEcCtD
Fluticasone Propionate—Angioedema—Imiquimod—skin cancer	0.000844	0.00202	CcSEcCtD
Fluticasone Propionate—Malaise—Imiquimod—skin cancer	0.000833	0.00199	CcSEcCtD
Fluticasone Propionate—PGR—head—skin cancer	0.000826	0.0215	CbGeAlD
Fluticasone Propionate—Influenza like illness—Docetaxel—skin cancer	0.000818	0.00195	CcSEcCtD
Fluticasone Propionate—Palpitations—Imiquimod—skin cancer	0.000816	0.00195	CcSEcCtD
Fluticasone Propionate—NR3C1—connective tissue—skin cancer	0.000809	0.021	CbGeAlD
Fluticasone Propionate—Irritability—Fluorouracil—skin cancer	0.000808	0.00193	CcSEcCtD
Fluticasone Propionate—Cough—Imiquimod—skin cancer	0.000806	0.00193	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000805	0.00192	CcSEcCtD
Fluticasone Propionate—Candida infection—Docetaxel—skin cancer	0.000804	0.00192	CcSEcCtD
Fluticasone Propionate—Abdominal distension—Temozolomide—skin cancer	0.0008	0.00191	CcSEcCtD
Fluticasone Propionate—Hypertension—Imiquimod—skin cancer	0.000797	0.00191	CcSEcCtD
Fluticasone Propionate—Pneumonia—Dactinomycin—skin cancer	0.000788	0.00188	CcSEcCtD
Fluticasone Propionate—Arthralgia—Imiquimod—skin cancer	0.000786	0.00188	CcSEcCtD
Fluticasone Propionate—Chest pain—Imiquimod—skin cancer	0.000786	0.00188	CcSEcCtD
Fluticasone Propionate—Anxiety—Imiquimod—skin cancer	0.000784	0.00187	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.000781	0.00187	CcSEcCtD
Fluticasone Propionate—Discomfort—Imiquimod—skin cancer	0.000777	0.00186	CcSEcCtD
Fluticasone Propionate—Dry mouth—Imiquimod—skin cancer	0.000769	0.00184	CcSEcCtD
Fluticasone Propionate—NR3C1—epithelium—skin cancer	0.000768	0.02	CbGeAlD
Fluticasone Propionate—PLA2G4A—lymph node—skin cancer	0.000765	0.0199	CbGeAlD
Fluticasone Propionate—Bronchitis—Temozolomide—skin cancer	0.000764	0.00183	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Fluorouracil—skin cancer	0.000757	0.00181	CcSEcCtD
Fluticasone Propionate—Oedema—Imiquimod—skin cancer	0.000754	0.0018	CcSEcCtD
Fluticasone Propionate—Lightheadedness—Docetaxel—skin cancer	0.000753	0.0018	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Bleomycin—skin cancer	0.00075	0.00179	CcSEcCtD
Fluticasone Propionate—Infection—Imiquimod—skin cancer	0.000749	0.00179	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Imiquimod—skin cancer	0.000739	0.00177	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Temozolomide—skin cancer	0.000738	0.00176	CcSEcCtD
Fluticasone Propionate—Tachycardia—Imiquimod—skin cancer	0.000736	0.00176	CcSEcCtD
Fluticasone Propionate—Skin disorder—Imiquimod—skin cancer	0.000732	0.00175	CcSEcCtD
Fluticasone Propionate—NR3C1—skin of body—skin cancer	0.00073	0.019	CbGeAlD
Fluticasone Propionate—Hyperglycaemia—Temozolomide—skin cancer	0.000717	0.00171	CcSEcCtD
Fluticasone Propionate—Pneumonia—Temozolomide—skin cancer	0.000712	0.0017	CcSEcCtD
Fluticasone Propionate—Infestation—Temozolomide—skin cancer	0.000708	0.00169	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Temozolomide—skin cancer	0.000708	0.00169	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Vemurafenib—skin cancer	0.000699	0.00167	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Dactinomycin—skin cancer	0.000698	0.00167	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000687	0.00164	CcSEcCtD
Fluticasone Propionate—Upper respiratory tract infection—Fluorouracil—skin cancer	0.00068	0.00163	CcSEcCtD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—KRT17—skin cancer	0.000677	0.0468	CbGpPWpGaD
Fluticasone Propionate—Dyspnoea—Imiquimod—skin cancer	0.000672	0.00161	CcSEcCtD
Fluticasone Propionate—NR3C1—mammalian vulva—skin cancer	0.000666	0.0173	CbGeAlD
Fluticasone Propionate—Sinusitis—Temozolomide—skin cancer	0.000664	0.00159	CcSEcCtD
Fluticasone Propionate—Pneumonia—Fluorouracil—skin cancer	0.000656	0.00157	CcSEcCtD
Fluticasone Propionate—Erythema—Bleomycin—skin cancer	0.000656	0.00157	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Fluorouracil—skin cancer	0.000653	0.00156	CcSEcCtD
Fluticasone Propionate—Infestation—Fluorouracil—skin cancer	0.000653	0.00156	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Vemurafenib—skin cancer	0.000651	0.00156	CcSEcCtD
Fluticasone Propionate—Atrial fibrillation—Docetaxel—skin cancer	0.000645	0.00154	CcSEcCtD
Fluticasone Propionate—Pain—Imiquimod—skin cancer	0.000645	0.00154	CcSEcCtD
Fluticasone Propionate—Dermatitis bullous—Docetaxel—skin cancer	0.000639	0.00153	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Fluorouracil—skin cancer	0.000634	0.00152	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Temozolomide—skin cancer	0.000633	0.00151	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Temozolomide—skin cancer	0.000631	0.00151	CcSEcCtD
Fluticasone Propionate—Pruritus—Vemurafenib—skin cancer	0.000625	0.00149	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Temozolomide—skin cancer	0.000625	0.00149	CcSEcCtD
Fluticasone Propionate—NR3C2—lymph node—skin cancer	0.000622	0.0162	CbGeAlD
Fluticasone Propionate—Feeling abnormal—Imiquimod—skin cancer	0.000621	0.00148	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Imiquimod—skin cancer	0.000616	0.00147	CcSEcCtD
Fluticasone Propionate—Epistaxis—Fluorouracil—skin cancer	0.000616	0.00147	CcSEcCtD
Fluticasone Propionate—Sinusitis—Fluorouracil—skin cancer	0.000612	0.00146	CcSEcCtD
Fluticasone Propionate—Erythema—Dactinomycin—skin cancer	0.000612	0.00146	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Bleomycin—skin cancer	0.000609	0.00145	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Vemurafenib—skin cancer	0.000605	0.00145	CcSEcCtD
Fluticasone Propionate—PGR—Ovarian Infertility Genes—MLH1—skin cancer	0.0006	0.0415	CbGpPWpGaD
Fluticasone Propionate—Urticaria—Imiquimod—skin cancer	0.000599	0.00143	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Imiquimod—skin cancer	0.000596	0.00142	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Imiquimod—skin cancer	0.000596	0.00142	CcSEcCtD
Fluticasone Propionate—Eye disorder—Temozolomide—skin cancer	0.000594	0.00142	CcSEcCtD
Fluticasone Propionate—Malaise—Bleomycin—skin cancer	0.000592	0.00141	CcSEcCtD
Fluticasone Propionate—NR3C1—lymphoid tissue—skin cancer	0.000591	0.0154	CbGeAlD
Fluticasone Propionate—Cardiac disorder—Temozolomide—skin cancer	0.00059	0.00141	CcSEcCtD
Fluticasone Propionate—Dizziness—Vemurafenib—skin cancer	0.000584	0.0014	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Fluorouracil—skin cancer	0.000583	0.00139	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Fluorouracil—skin cancer	0.000581	0.00139	CcSEcCtD
Fluticasone Propionate—PGR—lymph node—skin cancer	0.000578	0.015	CbGeAlD
Fluticasone Propionate—Immune system disorder—Temozolomide—skin cancer	0.000574	0.00137	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Temozolomide—skin cancer	0.000573	0.00137	CcSEcCtD
Fluticasone Propionate—Cough—Bleomycin—skin cancer	0.000573	0.00137	CcSEcCtD
Fluticasone Propionate—NR3C1—female reproductive system—skin cancer	0.00057	0.0148	CbGeAlD
Fluticasone Propionate—Ill-defined disorder—Dactinomycin—skin cancer	0.000568	0.00136	CcSEcCtD
Fluticasone Propionate—Vomiting—Vemurafenib—skin cancer	0.000562	0.00134	CcSEcCtD
Fluticasone Propionate—Chest pain—Bleomycin—skin cancer	0.000559	0.00133	CcSEcCtD
Fluticasone Propionate—Rash—Vemurafenib—skin cancer	0.000557	0.00133	CcSEcCtD
Fluticasone Propionate—Mental disorder—Temozolomide—skin cancer	0.000557	0.00133	CcSEcCtD
Fluticasone Propionate—Dermatitis—Vemurafenib—skin cancer	0.000557	0.00133	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Imiquimod—skin cancer	0.000555	0.00133	CcSEcCtD
Fluticasone Propionate—Headache—Vemurafenib—skin cancer	0.000554	0.00132	CcSEcCtD
Fluticasone Propionate—Malnutrition—Temozolomide—skin cancer	0.000553	0.00132	CcSEcCtD
Fluticasone Propionate—Erythema—Temozolomide—skin cancer	0.000553	0.00132	CcSEcCtD
Fluticasone Propionate—Discomfort—Bleomycin—skin cancer	0.000552	0.00132	CcSEcCtD
Fluticasone Propionate—Malaise—Dactinomycin—skin cancer	0.000552	0.00132	CcSEcCtD
Fluticasone Propionate—Cramp muscle—Docetaxel—skin cancer	0.00055	0.00132	CcSEcCtD
Fluticasone Propionate—Nasopharyngitis—Docetaxel—skin cancer	0.000547	0.00131	CcSEcCtD
Fluticasone Propionate—Triamcinolone—PTGS2—skin cancer	0.000543	0.0711	CrCbGaD
Fluticasone Propionate—Anaphylactic shock—Bleomycin—skin cancer	0.000535	0.00128	CcSEcCtD
Fluticasone Propionate—Oedema—Bleomycin—skin cancer	0.000535	0.00128	CcSEcCtD
Fluticasone Propionate—Pruritus—Imiquimod—skin cancer	0.000533	0.00127	CcSEcCtD
Fluticasone Propionate—Infection—Bleomycin—skin cancer	0.000532	0.00127	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—MITF—skin cancer	0.00053	0.0367	CbGpPWpGaD
Fluticasone Propionate—Nausea—Vemurafenib—skin cancer	0.000525	0.00125	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Fluorouracil—skin cancer	0.000523	0.00125	CcSEcCtD
Fluticasone Propionate—Vision blurred—Temozolomide—skin cancer	0.000522	0.00125	CcSEcCtD
Fluticasone Propionate—Bronchospasm—Docetaxel—skin cancer	0.00052	0.00124	CcSEcCtD
Fluticasone Propionate—Tremor—Temozolomide—skin cancer	0.000519	0.00124	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Imiquimod—skin cancer	0.000516	0.00123	CcSEcCtD
Fluticasone Propionate—Discomfort—Dactinomycin—skin cancer	0.000515	0.00123	CcSEcCtD
Fluticasone Propionate—Ill-defined disorder—Temozolomide—skin cancer	0.000514	0.00123	CcSEcCtD
Fluticasone Propionate—Erythema—Fluorouracil—skin cancer	0.00051	0.00122	CcSEcCtD
Fluticasone Propionate—Agitation—Temozolomide—skin cancer	0.000509	0.00122	CcSEcCtD
Fluticasone Propionate—Angioedema—Temozolomide—skin cancer	0.000506	0.00121	CcSEcCtD
Fluticasone Propionate—Oedema—Dactinomycin—skin cancer	0.000499	0.00119	CcSEcCtD
Fluticasone Propionate—Malaise—Temozolomide—skin cancer	0.000499	0.00119	CcSEcCtD
Fluticasone Propionate—Dizziness—Imiquimod—skin cancer	0.000498	0.00119	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGER4—skin cancer	0.000497	0.0343	CbGpPWpGaD
Fluticasone Propionate—Infection—Dactinomycin—skin cancer	0.000496	0.00119	CcSEcCtD
Fluticasone Propionate—Palpitations—Temozolomide—skin cancer	0.000489	0.00117	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000488	0.00117	CcSEcCtD
Fluticasone Propionate—NR3C1—FOXA2 and FOXA3 transcription factor networks—NKX2-1—skin cancer	0.000485	0.0335	CbGpPWpGaD
Fluticasone Propionate—Cough—Temozolomide—skin cancer	0.000483	0.00115	CcSEcCtD
Fluticasone Propionate—Vision blurred—Fluorouracil—skin cancer	0.000481	0.00115	CcSEcCtD
Fluticasone Propionate—Vomiting—Imiquimod—skin cancer	0.000479	0.00115	CcSEcCtD
Fluticasone Propionate—Hypertension—Temozolomide—skin cancer	0.000478	0.00114	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Bleomycin—skin cancer	0.000477	0.00114	CcSEcCtD
Fluticasone Propionate—NR3C1—head—skin cancer	0.000477	0.0124	CbGeAlD
Fluticasone Propionate—Rash—Imiquimod—skin cancer	0.000475	0.00114	CcSEcCtD
Fluticasone Propionate—Dermatitis—Imiquimod—skin cancer	0.000475	0.00113	CcSEcCtD
Fluticasone Propionate—Pneumonia—Docetaxel—skin cancer	0.000474	0.00113	CcSEcCtD
Fluticasone Propionate—Headache—Imiquimod—skin cancer	0.000472	0.00113	CcSEcCtD
Fluticasone Propionate—Arthralgia—Temozolomide—skin cancer	0.000471	0.00113	CcSEcCtD
Fluticasone Propionate—Infestation NOS—Docetaxel—skin cancer	0.000471	0.00113	CcSEcCtD
Fluticasone Propionate—Infestation—Docetaxel—skin cancer	0.000471	0.00113	CcSEcCtD
Fluticasone Propionate—Anxiety—Temozolomide—skin cancer	0.00047	0.00112	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000468	0.00112	CcSEcCtD
Fluticasone Propionate—Discomfort—Temozolomide—skin cancer	0.000466	0.00111	CcSEcCtD
Fluticasone Propionate—Dry mouth—Temozolomide—skin cancer	0.000461	0.0011	CcSEcCtD
Fluticasone Propionate—Pain—Bleomycin—skin cancer	0.000458	0.00109	CcSEcCtD
Fluticasone Propionate—Conjunctivitis—Docetaxel—skin cancer	0.000458	0.00109	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000455	0.00109	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Temozolomide—skin cancer	0.000452	0.00108	CcSEcCtD
Fluticasone Propionate—Oedema—Temozolomide—skin cancer	0.000452	0.00108	CcSEcCtD
Fluticasone Propionate—Infection—Temozolomide—skin cancer	0.000449	0.00107	CcSEcCtD
Fluticasone Propionate—Nausea—Imiquimod—skin cancer	0.000448	0.00107	CcSEcCtD
Fluticasone Propionate—Betamethasone—PTGS2—skin cancer	0.000445	0.0582	CrCbGaD
Fluticasone Propionate—Epistaxis—Docetaxel—skin cancer	0.000444	0.00106	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Temozolomide—skin cancer	0.000443	0.00106	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Bleomycin—skin cancer	0.000441	0.00105	CcSEcCtD
Fluticasone Propionate—Skin disorder—Temozolomide—skin cancer	0.000439	0.00105	CcSEcCtD
Fluticasone Propionate—Chest pain—Fluorouracil—skin cancer	0.000434	0.00104	CcSEcCtD
Fluticasone Propionate—PLA2G4A—PDGF Pathway—RASA1—skin cancer	0.000434	0.03	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—female reproductive system—skin cancer	0.000431	0.0112	CbGeAlD
Fluticasone Propionate—Discomfort—Fluorouracil—skin cancer	0.000429	0.00103	CcSEcCtD
Fluticasone Propionate—Pain—Dactinomycin—skin cancer	0.000427	0.00102	CcSEcCtD
Fluticasone Propionate—Urticaria—Bleomycin—skin cancer	0.000425	0.00102	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Bleomycin—skin cancer	0.000423	0.00101	CcSEcCtD
Fluticasone Propionate—Hypoaesthesia—Docetaxel—skin cancer	0.000421	0.00101	CcSEcCtD
Fluticasone Propionate—Pharyngitis—Docetaxel—skin cancer	0.00042	0.001	CcSEcCtD
Fluticasone Propionate—Oedema—Fluorouracil—skin cancer	0.000416	0.000995	CcSEcCtD
Fluticasone Propionate—Anaphylactic shock—Fluorouracil—skin cancer	0.000416	0.000995	CcSEcCtD
Fluticasone Propionate—Connective tissue disorder—Docetaxel—skin cancer	0.000415	0.000993	CcSEcCtD
Fluticasone Propionate—Infection—Fluorouracil—skin cancer	0.000413	0.000988	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Dactinomycin—skin cancer	0.000412	0.000983	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000412	0.000983	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Dactinomycin—skin cancer	0.000408	0.000976	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Fluorouracil—skin cancer	0.000408	0.000975	CcSEcCtD
Fluticasone Propionate—Tachycardia—Fluorouracil—skin cancer	0.000406	0.000971	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Temozolomide—skin cancer	0.000403	0.000962	CcSEcCtD
Fluticasone Propionate—Eye disorder—Docetaxel—skin cancer	0.000395	0.000944	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Dactinomycin—skin cancer	0.000395	0.000943	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Dactinomycin—skin cancer	0.000395	0.000943	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Bleomycin—skin cancer	0.000395	0.000943	CcSEcCtD
Fluticasone Propionate—Cardiac disorder—Docetaxel—skin cancer	0.000392	0.000938	CcSEcCtD
Fluticasone Propionate—Pain—Temozolomide—skin cancer	0.000386	0.000923	CcSEcCtD
Fluticasone Propionate—Immune system disorder—Docetaxel—skin cancer	0.000382	0.000913	CcSEcCtD
Fluticasone Propionate—Mediastinal disorder—Docetaxel—skin cancer	0.000381	0.000911	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000379	0.000906	CcSEcCtD
Fluticasone Propionate—Pruritus—Bleomycin—skin cancer	0.000379	0.000905	CcSEcCtD
Fluticasone Propionate—Arrhythmia—Docetaxel—skin cancer	0.000378	0.000903	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Temozolomide—skin cancer	0.000372	0.00089	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Fluorouracil—skin cancer	0.000371	0.000887	CcSEcCtD
Fluticasone Propionate—Mental disorder—Docetaxel—skin cancer	0.00037	0.000885	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Temozolomide—skin cancer	0.000369	0.000883	CcSEcCtD
Fluticasone Propionate—Malnutrition—Docetaxel—skin cancer	0.000368	0.00088	CcSEcCtD
Fluticasone Propionate—Erythema—Docetaxel—skin cancer	0.000368	0.00088	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Dactinomycin—skin cancer	0.000368	0.000879	CcSEcCtD
Fluticasone Propionate—Urticaria—Temozolomide—skin cancer	0.000359	0.000858	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Temozolomide—skin cancer	0.000357	0.000853	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Temozolomide—skin cancer	0.000357	0.000853	CcSEcCtD
Fluticasone Propionate—Pain—Fluorouracil—skin cancer	0.000356	0.000851	CcSEcCtD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—KRT5—skin cancer	0.000356	0.0246	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—ASIP—skin cancer	0.000355	0.0245	CbGpPWpGaD
Fluticasone Propionate—Muscle spasms—Docetaxel—skin cancer	0.000354	0.000846	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Fluorouracil—skin cancer	0.000343	0.00082	CcSEcCtD
Fluticasone Propionate—NR3C1—Endoderm Differentiation—NKX2-1—skin cancer	0.000342	0.0237	CbGpPWpGaD
Fluticasone Propionate—Diarrhoea—Dactinomycin—skin cancer	0.000342	0.000817	CcSEcCtD
Fluticasone Propionate—Vomiting—Bleomycin—skin cancer	0.00034	0.000814	CcSEcCtD
Fluticasone Propionate—Rash—Bleomycin—skin cancer	0.000338	0.000807	CcSEcCtD
Fluticasone Propionate—Dermatitis—Bleomycin—skin cancer	0.000337	0.000806	CcSEcCtD
Fluticasone Propionate—NR3C1—lymph node—skin cancer	0.000334	0.00868	CbGeAlD
Fluticasone Propionate—Hypersensitivity—Temozolomide—skin cancer	0.000333	0.000795	CcSEcCtD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—KRT14—skin cancer	0.000331	0.0229	CbGpPWpGaD
Fluticasone Propionate—Urticaria—Fluorouracil—skin cancer	0.000331	0.00079	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Fluorouracil—skin cancer	0.000329	0.000786	CcSEcCtD
Fluticasone Propionate—Palpitations—Docetaxel—skin cancer	0.000325	0.000777	CcSEcCtD
Fluticasone Propionate—Cough—Docetaxel—skin cancer	0.000321	0.000768	CcSEcCtD
Fluticasone Propionate—Pruritus—Temozolomide—skin cancer	0.00032	0.000764	CcSEcCtD
Fluticasone Propionate—Nausea—Bleomycin—skin cancer	0.000318	0.00076	CcSEcCtD
Fluticasone Propionate—Hypertension—Docetaxel—skin cancer	0.000318	0.000759	CcSEcCtD
Fluticasone Propionate—Vomiting—Dactinomycin—skin cancer	0.000318	0.000759	CcSEcCtD
Fluticasone Propionate—Rash—Dactinomycin—skin cancer	0.000315	0.000753	CcSEcCtD
Fluticasone Propionate—Chest pain—Docetaxel—skin cancer	0.000313	0.000749	CcSEcCtD
Fluticasone Propionate—Arthralgia—Docetaxel—skin cancer	0.000313	0.000749	CcSEcCtD
Fluticasone Propionate—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000311	0.000744	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Temozolomide—skin cancer	0.000309	0.000739	CcSEcCtD
Fluticasone Propionate—Hypersensitivity—Fluorouracil—skin cancer	0.000307	0.000733	CcSEcCtD
Fluticasone Propionate—Dry mouth—Docetaxel—skin cancer	0.000306	0.000732	CcSEcCtD
Fluticasone Propionate—PGR—Ovarian Infertility Genes—CDK4—skin cancer	0.000305	0.0211	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—RASA1—skin cancer	0.000303	0.021	CbGpPWpGaD
Fluticasone Propionate—Anaphylactic shock—Docetaxel—skin cancer	0.0003	0.000718	CcSEcCtD
Fluticasone Propionate—Oedema—Docetaxel—skin cancer	0.0003	0.000718	CcSEcCtD
Fluticasone Propionate—Dizziness—Temozolomide—skin cancer	0.000299	0.000714	CcSEcCtD
Fluticasone Propionate—Infection—Docetaxel—skin cancer	0.000298	0.000713	CcSEcCtD
Fluticasone Propionate—Nausea—Dactinomycin—skin cancer	0.000297	0.000709	CcSEcCtD
Fluticasone Propionate—Nervous system disorder—Docetaxel—skin cancer	0.000295	0.000704	CcSEcCtD
Fluticasone Propionate—Pruritus—Fluorouracil—skin cancer	0.000294	0.000704	CcSEcCtD
Fluticasone Propionate—Tachycardia—Docetaxel—skin cancer	0.000293	0.000701	CcSEcCtD
Fluticasone Propionate—Skin disorder—Docetaxel—skin cancer	0.000292	0.000697	CcSEcCtD
Fluticasone Propionate—Vomiting—Temozolomide—skin cancer	0.000287	0.000686	CcSEcCtD
Fluticasone Propionate—Rash—Temozolomide—skin cancer	0.000285	0.000681	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Fluorouracil—skin cancer	0.000285	0.000681	CcSEcCtD
Fluticasone Propionate—Dermatitis—Temozolomide—skin cancer	0.000285	0.00068	CcSEcCtD
Fluticasone Propionate—Headache—Temozolomide—skin cancer	0.000283	0.000676	CcSEcCtD
Fluticasone Propionate—Dizziness—Fluorouracil—skin cancer	0.000275	0.000658	CcSEcCtD
Fluticasone Propionate—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000274	0.000654	CcSEcCtD
Fluticasone Propionate—Nausea—Temozolomide—skin cancer	0.000268	0.000641	CcSEcCtD
Fluticasone Propionate—Dyspnoea—Docetaxel—skin cancer	0.000268	0.00064	CcSEcCtD
Fluticasone Propionate—Vomiting—Fluorouracil—skin cancer	0.000265	0.000632	CcSEcCtD
Fluticasone Propionate—Rash—Fluorouracil—skin cancer	0.000262	0.000627	CcSEcCtD
Fluticasone Propionate—Dermatitis—Fluorouracil—skin cancer	0.000262	0.000627	CcSEcCtD
Fluticasone Propionate—Headache—Fluorouracil—skin cancer	0.000261	0.000623	CcSEcCtD
Fluticasone Propionate—Dexamethasone—PTGS2—skin cancer	0.000259	0.0339	CrCbGaD
Fluticasone Propionate—Pain—Docetaxel—skin cancer	0.000257	0.000614	CcSEcCtD
Fluticasone Propionate—Feeling abnormal—Docetaxel—skin cancer	0.000248	0.000592	CcSEcCtD
Fluticasone Propionate—Nausea—Fluorouracil—skin cancer	0.000247	0.000591	CcSEcCtD
Fluticasone Propionate—Gastrointestinal pain—Docetaxel—skin cancer	0.000246	0.000587	CcSEcCtD
Fluticasone Propionate—Abdominal pain—Docetaxel—skin cancer	0.000237	0.000567	CcSEcCtD
Fluticasone Propionate—Body temperature increased—Docetaxel—skin cancer	0.000237	0.000567	CcSEcCtD
Fluticasone Propionate—NR3C1—Serotonin Receptor 4/6/7 and NR3C Signaling—BRAF—skin cancer	0.000237	0.0164	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—AGE/RAGE pathway—FOXO4—skin cancer	0.000233	0.0161	CbGpPWpGaD
Fluticasone Propionate—Hypersensitivity—Docetaxel—skin cancer	0.000221	0.000529	CcSEcCtD
Fluticasone Propionate—NR3C1—Adipogenesis—PLIN2—skin cancer	0.000215	0.0149	CbGpPWpGaD
Fluticasone Propionate—Pruritus—Docetaxel—skin cancer	0.000213	0.000508	CcSEcCtD
Fluticasone Propionate—Diarrhoea—Docetaxel—skin cancer	0.000206	0.000491	CcSEcCtD
Fluticasone Propionate—Dizziness—Docetaxel—skin cancer	0.000199	0.000475	CcSEcCtD
Fluticasone Propionate—Vomiting—Docetaxel—skin cancer	0.000191	0.000456	CcSEcCtD
Fluticasone Propionate—Rash—Docetaxel—skin cancer	0.000189	0.000453	CcSEcCtD
Fluticasone Propionate—Dermatitis—Docetaxel—skin cancer	0.000189	0.000452	CcSEcCtD
Fluticasone Propionate—Headache—Docetaxel—skin cancer	0.000188	0.00045	CcSEcCtD
Fluticasone Propionate—PLA2G4A—Prostaglandin Synthesis and Regulation—PTGS2—skin cancer	0.000187	0.013	CbGpPWpGaD
Fluticasone Propionate—Nausea—Docetaxel—skin cancer	0.000178	0.000426	CcSEcCtD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—RASA1—skin cancer	0.000171	0.0118	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—PTGS2—skin cancer	0.000166	0.0115	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—FOXO4—skin cancer	0.000147	0.0101	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—FOXO4—skin cancer	0.00014	0.0097	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Arachidonic acid metabolism—PTGS2—skin cancer	0.000125	0.00861	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000122	0.00846	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000116	0.00802	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling mediated by p38-alpha and p38-beta—TP53—skin cancer	9.86e-05	0.00682	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—p38 MAPK Signaling Pathway—HRAS—skin cancer	9.65e-05	0.00668	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	9.33e-05	0.00645	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—RHOU—skin cancer	9.26e-05	0.0064	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Transcription factor regulation in adipogenesis—IL6—skin cancer	9.26e-05	0.0064	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGF Pathway—HRAS—skin cancer	8.65e-05	0.00598	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Regulation of nuclear SMAD2/3 signaling—CDK4—skin cancer	8.38e-05	0.0058	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—RHOU—skin cancer	7.57e-05	0.00523	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—BRAF—skin cancer	7.41e-05	0.00512	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—CDKN2A—skin cancer	7.2e-05	0.00498	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—PTCH2—skin cancer	6.25e-05	0.00433	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Fc-epsilon receptor I signaling in mast cells—HRAS—skin cancer	6.05e-05	0.00418	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	5.96e-05	0.00412	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Endothelins—HRAS—skin cancer	5.89e-05	0.00408	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—NRAS—skin cancer	4.87e-05	0.00337	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—NRAS—skin cancer	4.66e-05	0.00322	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PTCH2—skin cancer	4.52e-05	0.00313	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—MC1R—skin cancer	4.52e-05	0.00313	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	4.26e-05	0.00295	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—KRAS—skin cancer	4.19e-05	0.0029	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PLIN2—skin cancer	4.15e-05	0.00287	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—TP53—skin cancer	4.01e-05	0.00277	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—KRAS—skin cancer	4.01e-05	0.00277	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PTCH2—skin cancer	3.69e-05	0.00255	CbGpPWpGaD
Fluticasone Propionate—NR3C1—AP-1 transcription factor network—IL6—skin cancer	3.67e-05	0.00254	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—HRAS—skin cancer	3.57e-05	0.00247	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—TP53—skin cancer	3.53e-05	0.00244	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—GLI2—skin cancer	3.43e-05	0.00237	CbGpPWpGaD
Fluticasone Propionate—NR3C2—Gene Expression—ERCC2—skin cancer	3.42e-05	0.00236	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling by ERBB4—IL6—skin cancer	3.41e-05	0.00236	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—PDGFR-beta signaling pathway—HRAS—skin cancer	3.41e-05	0.00236	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—CSPG4—skin cancer	3.35e-05	0.00232	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—MC1R—skin cancer	3.27e-05	0.00226	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Glucocorticoid receptor regulatory network—IL6—skin cancer	3.23e-05	0.00224	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—GLI1—skin cancer	3.22e-05	0.00223	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—SHH—skin cancer	3.22e-05	0.00223	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—SUFU—skin cancer	3.05e-05	0.00211	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—PTCH1—skin cancer	3.05e-05	0.00211	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—SMO—skin cancer	3.05e-05	0.00211	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—PTGER4—skin cancer	2.97e-05	0.00206	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PLIN2—skin cancer	2.89e-05	0.002	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.85e-05	0.00197	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—GLI2—skin cancer	2.8e-05	0.00194	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—MC1R—skin cancer	2.67e-05	0.00185	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—GLI1—skin cancer	2.63e-05	0.00182	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.54e-05	0.00175	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—SUFU—skin cancer	2.5e-05	0.00173	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—CSPG4—skin cancer	2.33e-05	0.00161	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—SHH—skin cancer	2.33e-05	0.00161	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—RASA1—skin cancer	2.32e-05	0.0016	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—ENO2—skin cancer	2.28e-05	0.00157	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Adipogenesis—IL6—skin cancer	2.24e-05	0.00155	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—SMO—skin cancer	2.21e-05	0.00153	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PTCH1—skin cancer	2.21e-05	0.00153	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—PTGER4—skin cancer	2.15e-05	0.00149	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PLIN2—skin cancer	2.09e-05	0.00145	CbGpPWpGaD
Fluticasone Propionate—PGR—Gene Expression—ERCC2—skin cancer	2.08e-05	0.00144	CbGpPWpGaD
Fluticasone Propionate—NR3C1—SIDS Susceptibility Pathways—IL6—skin cancer	1.93e-05	0.00134	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—SHH—skin cancer	1.9e-05	0.00132	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—FOXO4—skin cancer	1.9e-05	0.00131	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—RASA1—skin cancer	1.89e-05	0.00131	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—SMO—skin cancer	1.8e-05	0.00125	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PTCH1—skin cancer	1.8e-05	0.00125	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.78e-05	0.00123	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—PTGER4—skin cancer	1.76e-05	0.00121	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—CSPG4—skin cancer	1.69e-05	0.00117	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—ENO2—skin cancer	1.59e-05	0.0011	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—FOXO4—skin cancer	1.55e-05	0.00107	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—NRAS—skin cancer	1.52e-05	0.00105	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—ERCC2—skin cancer	1.32e-05	0.000914	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—KRAS—skin cancer	1.31e-05	0.000906	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TERT—skin cancer	1.27e-05	0.000877	CbGpPWpGaD
Fluticasone Propionate—NR3C1—Gene Expression—ERCC2—skin cancer	1.2e-05	0.000832	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—TP53—skin cancer	1.16e-05	0.000805	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—ENO2—skin cancer	1.15e-05	0.000793	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Hemostasis—HRAS—skin cancer	1.11e-05	0.00077	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TERT—skin cancer	1.04e-05	0.000717	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—BRAF—skin cancer	1e-05	0.000695	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PLIN2—skin cancer	9.73e-06	0.000673	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—ERCC2—skin cancer	9.21e-06	0.000637	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—NRAS—skin cancer	8.73e-06	0.000604	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—BRAF—skin cancer	8.21e-06	0.000568	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Metabolism—PTGS2—skin cancer	7.93e-06	0.000548	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—CSPG4—skin cancer	7.84e-06	0.000542	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—KRAS—skin cancer	7.51e-06	0.00052	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—ERCC2—skin cancer	6.66e-06	0.000461	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—HRAS—skin cancer	6.39e-06	0.000442	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—NRAS—skin cancer	6.31e-06	0.000437	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling by GPCR—IL6—skin cancer	6.11e-06	0.000423	CbGpPWpGaD
Fluticasone Propionate—CYP3A7—Metabolism—PTGS2—skin cancer	5.52e-06	0.000382	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—KRAS—skin cancer	5.43e-06	0.000376	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—ENO2—skin cancer	5.33e-06	0.000369	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—NRAS—skin cancer	5.16e-06	0.000357	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—TP53—skin cancer	4.83e-06	0.000334	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—HRAS—skin cancer	4.62e-06	0.000319	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—KRAS—skin cancer	4.44e-06	0.000307	CbGpPWpGaD
Fluticasone Propionate—PGR—Signaling Pathways—IL6—skin cancer	4.42e-06	0.000306	CbGpPWpGaD
Fluticasone Propionate—CYP3A5—Metabolism—PTGS2—skin cancer	3.99e-06	0.000276	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—TP53—skin cancer	3.95e-06	0.000273	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—HRAS—skin cancer	3.77e-06	0.000261	CbGpPWpGaD
Fluticasone Propionate—PLA2G4A—Signaling Pathways—IL6—skin cancer	3.61e-06	0.00025	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—ERCC2—skin cancer	3.1e-06	0.000214	CbGpPWpGaD
Fluticasone Propionate—CYP3A4—Metabolism—PTGS2—skin cancer	1.86e-06	0.000128	CbGpPWpGaD
